Industry Leader In Transdermal Technology

ProsolusProSolus®, Inc. (“ProSolus”) has significantly improved the wearability of transdermal patches, offering more desirable, compact sizes that stay in place while working effectively. Few therapies on the market today are as effective or easy to use as ProSolus’ noninvasive and comfortable transdermal patches. Our state-of-the-art development and testing facility is capable of producing more than 10 million patches per year, and our primary focus lies in Pressure Sensitive Adhesive (PSA) technology and novel Hydrogel technology.

The ProSolus formulation team holds more than 35 patents in the transdermal and topical technology space and we have a proven track record of product commercialization. We are actively seeking strategic partnerships to out-license products and/or provide resources to commercialize products through:

  • Custom blending
  • Coating
  • Slitting
  • Die-cutting
  • Packaging
  • Full testing of products

About ProSolus®

Year Founded

2015

Specialization

Offers unrivaled expertise in the development and manufacturing of sophisticated and convenient transdermal/topical drug delivery systems (TDDS).

Leadership

Juan MantelleJuan Mantelle
Chief Operating Officer

Commercial Office

10999 IH 10 West
Suite 1000
San Antonio, TX 78230

Partnership Inquiries

o: 305.514.0271
c: 305.772.6652
e: [email protected]

Visit ProSolusPharma.com